Back to Directory
TauC3 Biologics
Stevenage
Founded 2019
Antibody immunotherapy targeting toxic tau for neurodegenerative disease
TauC3 Biologics is a preclinical biopharmaceutical company developing an antibody-based immunotherapy that targets tauC3, a toxic, truncated form of the tau protein implicated in neurodegenerative disease.
Its lead candidate, TBL-100, is a humanized monoclonal antibody developed with LifeArc, designed to selectively remove pathogenic tau while sparing healthy full-length tau.
The company is preparing for clinical development in frontotemporal dementia, with planned expansion into progressive supranuclear palsy and Alzheimer's disease.